Abstract | OBJECTIVES: METHODS: We enrolled 14 male PD patients. The mean age of patients was 73 years (61-77 years), the Hoehn-Yahr stage was 2 (2-3), and disease duration was 9 years (3-28 years). The effects of istradefylline (20 mg/d) on LUTSs in PD patients with motor complications after 3, 6, and 12 months of therapy were evaluated based on the International Prostate Symptom Score and Overactive Bladder Symptom Score before and after its administration. RESULTS: Motor symptoms significantly improved at 12 months' administration ( Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale part III: 30.0 ± 12.9 vs 13.8 ± 8.1; P < 0.01). Significant improvements were also observed in the answers provided on urinary questionnaires (International Prostate Symptom Score, 14.4 ± 7.6 vs 8.5 ± 6.8; Overactive Bladder Symptom Score, 6.9 ± 2.8 vs 5.5 ± 3.7; P < 0.05). Nighttime urinary frequency and the percentage of the nocturnal urine volume also improved significantly at 3 months' administration (P < 0.01). CONCLUSIONS:
Istradefylline effectively improved not only motor symptoms, but also LUTSs in patients with PD.
|
Authors | Takeya Kitta, Ichiro Yabe, Yukiko Kanno, Madoka Higuchi, Mifuka Ouchi, Mio Togo, Kimihiko Moriya, Ikuko Takahashi, Masaaki Matsushima, Hidenao Sasaki, Nobuo Shinohara |
Journal | Clinical neuropharmacology
(Clin Neuropharmacol)
2018 May/Jun
Vol. 41
Issue 3
Pg. 98-102
ISSN: 1537-162X [Electronic] United States |
PMID | 29672326
(Publication Type: Journal Article)
|
Chemical References |
- Adenosine A2 Receptor Antagonists
- Purines
- istradefylline
|
Topics |
- Adenosine A2 Receptor Antagonists
(therapeutic use)
- Aged
- Humans
- Longitudinal Studies
- Lower Urinary Tract Symptoms
(drug therapy, etiology)
- Male
- Middle Aged
- Parkinson Disease
(complications)
- Purines
(therapeutic use)
- Quality of Life
- Severity of Illness Index
- Surveys and Questionnaires
- Time Factors
- Treatment Outcome
|